[Skip to Content]

Upstate Active Clinical Trials

Study Title:

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

What is the purpose of the study?

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

Upstate Institutional Review Board (IRB) Number:

840338

Study/Protocol ID:

NRG-BR003

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

Where will the study take place?

Upstate Cancer Center - All Procedures

ClinicalTrials.Gov ID:

NCT02488967

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Erinn Mcdowell, MS, CCRP
Phone: 315-464-8230
Email: mcdowele@upstate.edu

Return to Previous Page || Search Again

Top